Cases & Deals

  • Home
  • Practices
  • AbbVie successfully defends HUMIRA® formulation patent against four IPR petitions filed by Coherus

Share

AbbVie successfully defends HUMIRA® formulation patent against four IPR petitions filed by Coherus

September 2017

Client(s) AbbVie Inc.

Jones Day served as lead counsel and successfully defended AbbVie in connection with four (4) separate inter partes review (IPR) petitions brought by Coherus Biosciences, Inc. against U.S. Patent No. 9,085,619, which is related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®. Coherus is developing a biosimilar version of HUMIRA®. Following the filing of the Patent Owner's Preliminary Responses by AbbVie, the PTAB denied institution of each of Coherus' IPR petitions with regard to all of the challenged claims.

Coherus, Inc. v. AbbVie Biotechnology, Inc., IPR2017-00822, -00823, -01008, -01009 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.